No elevated risk for depression, anxiety or suicidality with secukinumab in a pooled analysis of data from 10 clinical studies in moderate‐to‐severe plaque psoriasis

Saved in:
Bibliographic Details
Published inBritish journal of dermatology (1951) Vol. 178; no. 2; pp. e105 - e107
Main Authors Strober, B.E., Langley, R.G.B., Menter, A., Magid, M., Porter, B., Fox, T., Safi, J., Papavassilis, C.
Format Journal Article
LanguageEnglish
Published England Oxford University Press 01.02.2018
Subjects
Antibodies, Monoclonal - adverse effects
Anxiety
Anxiety Disorders - chemically induced
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Data processing
Depressive Disorder - chemically induced
Dermatologic Agents - adverse effects
Double-Blind Method
Humans
Mental depression
Monoclonal antibodies
Psoriasis
Psoriasis - drug therapy
Randomized Controlled Trials as Topic
Risk Factors
Suicidal Ideation
Suicides & suicide attempts
Online AccessGet full text

Cover

More Information
Bibliography:SourceType-Other Sources-1
ObjectType-Article-2
content type line 63
ObjectType-Feature-1
ObjectType-Correspondence-3
ISSN:0007-0963
1365-2133
DOI:10.1111/bjd.16051